SAGE - Sage Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 59.44B
Enterprise Value 38.13B
Trailing P/E N/A
Forward P/E 1-15.15
PEG Ratio (5 yr expected) 1-1.06
Price/Sales (ttm)104.02
Price/Book (mrq)7.14
Enterprise Value/Revenue 389.59
Enterprise Value/EBITDA 6-16.81

Trading Information

Stock Price History

Beta (3Y Monthly) 2.64
52-Week Change 310.48%
S&P500 52-Week Change 36.70%
52 Week High 3193.56
52 Week Low 379.88
50-Day Moving Average 3179.21
200-Day Moving Average 3160.53

Share Statistics

Avg Vol (3 month) 3385.89k
Avg Vol (10 day) 3323.6k
Shares Outstanding 5N/A
Float 49.81M
% Held by Insiders 12.71%
% Held by Institutions 198.75%
Shares Short (Jun 28, 2019) 45.33M
Short Ratio (Jun 28, 2019) 414.7
Short % of Float (Jun 28, 2019) 415.17%
Short % of Shares Outstanding (Jun 28, 2019) 410.42%
Shares Short (prior month May 31, 2019) 44.6M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-534.47%

Management Effectiveness

Return on Assets (ttm)-24.02%
Return on Equity (ttm)-38.82%

Income Statement

Revenue (ttm)90.74M
Revenue Per Share (ttm)1.92
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)-191.83M
EBITDA -483.66M
Net Income Avi to Common (ttm)-461.69M
Diluted EPS (ttm)-9.79
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)1.35B
Total Cash Per Share (mrq)26.42
Total Debt (mrq)41.68M
Total Debt/Equity (mrq)3.16
Current Ratio (mrq)20.06
Book Value Per Share (mrq)25.86

Cash Flow Statement

Operating Cash Flow (ttm)-332.03M
Levered Free Cash Flow (ttm)-160.35M